跳至主要内容
临床试验/DRKS00029129
DRKS00029129招募中未知

Transorbital electrical stimulation as a vision restoration tool in patients with significant optic atrophy due to primary open-angle glaucoma. Acronym: VIROA (Vision Restoration in Optic Atrophy) - VIRON (Vision Restoration in Optic Neuropathy)

niversitätsmedizin Göttingen0 个研究点目标入组 300 人开始时间: 2022年11月10日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
40 Years 至 79 Years(—)
性别
All

入选标准

  • •Patients with diagnosis of primary open-angle glaucoma (according to the EGS criteria), glaucomatous optic atrophy and significant visual field impairment typical for glaucoma (mean defect >5dB)
  • •- Age >/= 40 years
  • •- Typical glaucomatous optic disc damage and visual field loss in one eye and either visual field loss or typical glaucomatous optic disc damage or both in the other eye
  • •- Familiarity with static perimetry (at least 5 examinations before starting this study)
  • •- Intraocular pressure <22 mmHg (topically treated or untreated)
  • •- signed informed consent and willingness to participate

排除标准

  • •- any other type of glaucoma except POWG
  • •- Age > 80 years
  • •- Visual field defect (mean defect) >/= 22dB or <5dB
  • •- Visual acuity decimal <0.2
  • •- Deviation of the mean defect (MD) of >2dB between screening (day -28) and the first initial examination (day -21)
  • •- Vision-related affection of the refracting media (e.g., cataract or corneal scars) that would affect the assessment of study effects
  • •- other ophthalmological reasons for visual impairment (e.g. age-related macular degeneration, diabetic retinopathy, optic atrophy of other origins apart from POAG, vascular occlusion)
  • •- any surgical procedure within 3 months prior to study entry
  • •- Status post glaucoma surgery or eye pressure-reducing laser or cryotherapy within 3 months prior to study entry
  • •- Status post intraocular surgery within 6 months prior to study entry
  • •- Any glaucoma medication change within 3 months prior to study entry and/or use of more than 2 local (or oral) antihypertensive drugs at baseline
  • •- Refractive error: spherical equivalent greater than +/-6dpt, cylinder value greater than 3dpt
  • •- Patients with comprehensible visual field impairments caused by ptosis or dermatochalasis.
  • •- Women of childbearing age without contraception, pregnancy, breastfeeding mothers
  • •- neurological diseases (stroke, seizures, epilepsy, status post brain surgery, pathological nystagmus)
  • •- uncontrolled high blood pressure (>160 mmHg)
  • •- Claustrophobia
  • •- Electronic implants (e.g. pacemakers, brain implants) or metallic artefacts on the head
  • •- Mental illnesses (e.g. schizophrenia, addictions, substance dependency) that do not allow the person to assess the nature and scope as well as possible consequences of the clinical study
  • •- Inability to understand the nature of the study and provide valid informed consent
  • •- Signs that the patient will probably not attend the necessary visits (e.g. lack of willingness to cooperate, lack of compliance)
  • •- Participation in other clinical studies within the last 12 weeks before the start of the study
  • •- Autoimmune diseases in the acute stage
  • •- Acute (intra-)ocular inflammation in the study or companion eye
  • •- Therapy with opiates, calcium antagonists or benzodiazepines
  • •- Unwillingness for an MRI examination

研究者

发起方
niversitätsmedizin Göttingen

相似试验